LebeauxDSèneD.Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol. 2012;26:449-458.
2.
BischoffLDerkCT.Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008;47:29-35.
3.
RomanoCRubegniPDe AloeG. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol. 2003;17:10-13.
4.
RossettiFZulianFDall’AmicoRMessinaCMontiniGZacchelloF.Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplantation. 1995;59:149-151.
5.
FimianiMRubegniPD’AscenzoG. Extracorporeal photochemotherapy in the early treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1994;31:828-830.
6.
BesnierDPChabannesDMussiniJMDupasBEsnaultVL.Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol Photoimmunol Photomed. 2002;18:36-41.
7.
PrinzBNachbarFPlewigG.Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res. 1994;287:48-52.
8.
Matucci-CerinicMDentonCPFurstDE. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32-38.
9.
KurgyisZVargaRSickILangMURuzickaTSárdyM.Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis. Acta Derm Venereol. 2011;91:716-717.
10.
NagaiYHasegawaMHattoriTOkadaETagoOIshikawaO.Bosentan for digital ulcers in patients with systemic sclerosis. J Dermatol. 2012;39:48-51.
